Assembly Financial Statements From 2010 to 2026
| ASMB Stock | USD 29.37 0.54 1.81% |
Check Assembly Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Assembly Biosciences' main balance sheet or income statement drivers, such as , as well as many indicators such as . Assembly financial statements analysis is a perfect complement when working with Assembly Biosciences Valuation or Volatility modules.
Check out the analysis of Assembly Biosciences Correlation against competitors. Assembly Biosciences Company Current Valuation Analysis
Assembly Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Assembly Biosciences Current Valuation | 234.75 M |
Most of Assembly Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Assembly Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Assembly Biosciences has a Current Valuation of 234.75 M. This is 98.37% lower than that of the Biotechnology sector and 94.95% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.59% higher than that of the company.
Assembly Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Assembly Biosciences's current stock value. Our valuation model uses many indicators to compare Assembly Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Assembly Biosciences competition to find correlations between indicators driving Assembly Biosciences's intrinsic value. More Info.Assembly Biosciences is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Assembly Biosciences' earnings, one of the primary drivers of an investment's value.About Assembly Biosciences Financial Statements
Assembly Biosciences stakeholders use historical fundamental indicators, such as Assembly Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Assembly Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Assembly Biosciences' assets and liabilities are reflected in the revenues and expenses on Assembly Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Assembly Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus infection in the United States. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Assembly Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 70 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:Check out the analysis of Assembly Biosciences Correlation against competitors. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.